JPH04504253A - ＩｇＭ抗体の安定化のための配合物 - Google Patents

ＩｇＭ抗体の安定化のための配合物

Info

Publication number: JPH04504253A
Authority: JP; Japan
Prior art keywords: formulation; paragraph; igm; formulation according; sodium
Prior art date: 1989-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2505100A

Other languages

English (en)

Japanese (ja)

Inventor

ボルマー，サリイ

マテイス，ジエフリイ・エイ

フイリツプス，クリストフアー・ピー

Original Assignee

セントカー・インコーポレーテツド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-27

Filing date

1990-03-13

Publication date

1992-07-30

1990-03-13 Application filed by セントカー・インコーポレーテツド filed Critical セントカー・インコーポレーテツド

1992-07-30 Publication of JPH04504253A publication Critical patent/JPH04504253A/ja

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 71
238000009472 formulation Methods 0.000 title claims description 70
230000006641 stabilisation Effects 0.000 title description 3
238000011105 stabilization Methods 0.000 title description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 51
239000011780 sodium chloride Substances 0.000 claims description 28
239000000243 solution Substances 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000623 proteins and genes Proteins 0.000 claims description 19
102000008100 Human Serum Albumin Human genes 0.000 claims description 17
108091006905 Human Serum Albumin Proteins 0.000 claims description 17
229960005480 sodium caprylate Drugs 0.000 claims description 16
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 16
238000001291 vacuum drying Methods 0.000 claims description 12
108060003951 Immunoglobulin Proteins 0.000 claims description 11
239000000872 buffer Substances 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 11
102000018358 immunoglobulin Human genes 0.000 claims description 11
239000000843 powder Substances 0.000 claims description 11
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 11
125000003047 N-acetyl group Chemical group 0.000 claims description 10
229960000281 trometamol Drugs 0.000 claims description 10
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
239000008363 phosphate buffer Substances 0.000 claims description 5
239000011734 sodium Substances 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
239000001488 sodium phosphate Substances 0.000 claims description 5
229910000162 sodium phosphate Inorganic materials 0.000 claims description 5
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
102000009027 Albumins Human genes 0.000 claims description 3
108010088751 Albumins Proteins 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
229910052698 phosphorus Inorganic materials 0.000 claims description 3
DZTHIGRZJZPRDV-UHFFFAOYSA-M N-acetyltryptophanate Chemical compound C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-M 0.000 claims description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
239000011574 phosphorus Substances 0.000 claims description 2
239000007972 injectable composition Substances 0.000 claims 4
229940102223 injectable solution Drugs 0.000 claims 2
241000771382 Anthidium toro Species 0.000 claims 1
229910019142 PO4 Inorganic materials 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
QIVBCDIJIAJPQS-UHFFFAOYSA-M tryptophanate Chemical compound C1=CC=C2C(CC(N)C([O-])=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-M 0.000 claims 1
239000000047 product Substances 0.000 description 23
238000002360 preparation method Methods 0.000 description 17
239000007788 liquid Substances 0.000 description 12
239000002245 particle Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
239000000126 substance Substances 0.000 description 7
230000000087 stabilizing effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000000902 placebo Substances 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
230000004071 biological effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
230000005965 immune activity Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000012263 liquid product Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
DKLRSEXTALBASW-UHFFFAOYSA-I [Cl-].[Th+4].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [Cl-].[Th+4].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] DKLRSEXTALBASW-UHFFFAOYSA-I 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003990 capacitor Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000013026 undiluted sample Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP2505100A 1989-03-27 1990-03-13 ＩｇＭ抗体の安定化のための配合物 Pending JPH04504253A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32857989A	1989-03-27	1989-03-27
US328,579		1989-03-27

Publications (1)

Publication Number	Publication Date
JPH04504253A true JPH04504253A (ja)	1992-07-30

Family

ID=23281559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2505100A Pending JPH04504253A (ja)	1989-03-27	1990-03-13	ＩｇＭ抗体の安定化のための配合物

Country Status (4)

Country	Link
EP (1)	EP0465513A1 (fr)
JP (1)	JPH04504253A (fr)
CA (1)	CA2049342A1 (fr)
WO (1)	WO1990011091A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008303176A (ja) *	2007-06-07	2008-12-18	Kobayashi Pharmaceut Co Ltd	タンパク質含有組成物
JP2014520535A (ja) *	2011-07-05	2014-08-25	ノボザイムスバイオファーマデーコーアクティーゼルスカブ	アルブミン製剤及び用途
JP2017527531A (ja) *	2014-10-06	2017-09-21	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	担体および抗体からなる組成物およびその製造および使用方法
JP2018523670A (ja) *	2015-08-18	2018-08-23	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	キャリア結合剤組成物およびそれを作製および使用する方法
US10279036B2 (en)	2012-10-01	2019-05-07	Mayo Foundation For Medical Education And Research	Antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, and methods of making and using the same
US10561726B2 (en)	2015-10-06	2020-02-18	Vavotar Life Sciences LLC	Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
US10765741B2 (en)	2011-05-09	2020-09-08	Mayo Foundation For Medical Education And Research	Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab
US11160876B2 (en)	2016-09-01	2021-11-02	Mayo Foundation For Medical Education And Research	Methods and compositions for targeting t-cell cancers
US11241387B2 (en)	2015-08-18	2022-02-08	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
US11285221B2 (en)	2014-06-16	2022-03-29	Mayo Foundation For Medical Education And Research	Treating myelomas
US11305020B2 (en)	2016-03-21	2022-04-19	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
US11311631B2 (en)	2016-09-06	2022-04-26	Mayo Foundation For Medical Education And Research	Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
US11427637B2 (en)	2016-09-06	2022-08-30	Mayo Foundation For Medical Education And Research	Methods of treating PD-L1 expressing cancer
US11548946B2 (en)	2016-09-01	2023-01-10	Mayo Foundation For Medical Education And Research	Carrier-PD-L1 binding agent compositions for treating cancers
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US11878061B2 (en)	2016-03-21	2024-01-23	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US12403119B2 (en)	2014-06-13	2025-09-02	Mayo Foundation For Medical Education And Research	Treating lymphomas

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2086531A1 (fr) *	1990-07-03	1992-01-04	Ebo S. Bos	Compose immunoreactif
JPH0565233A (ja) *	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	モノクローナル抗体含有凍結乾燥製剤
WO1993006862A1 (fr) *	1991-10-11	1993-04-15	Toray Industries, Inc.	Composition a base d'anticorps
CA2127877A1 (fr) *	1992-01-21	1993-07-22	Robert M. Platz	Procede ameliore pour la preparation de medicaments polypeptidiques microfins
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
AU2444899A (en) *	1998-01-22	1999-08-09	Astrazeneca Ab	Pharmaceutical formulation comprising an antibody and a citrate buffer
DE60139944D1 (de)	2000-10-12	2009-10-29	Genentech Inc	Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
ATE414537T1 (de) *	2001-08-29	2008-12-15	Chugai Pharmaceutical Co Ltd	Antikörper enthaltende stabilisierte zubereitungen
US20030138417A1 (en)	2001-11-08	2003-07-24	Kaisheva Elizabet A.	Stable liquid pharmaceutical formulation of IgG antibodies
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
PT1610820E (pt)	2003-04-04	2010-12-16	Novartis Ag	Formulações de elevada concentração de anticorpos e proteínas
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
PE20120359A1 (es)	2009-03-06	2012-04-13	Genentech Inc	Formulacion con anticuerpo
PT2542257T (pt)	2010-03-01	2017-10-09	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
CN102946904A (zh)	2010-06-18	2013-02-27	埃克斯生物科技公司	关节炎治疗
PH12013500316A1 (en)	2010-08-23	2016-09-02	Janssen Biotech Inc	Treatment for neoplastic diseases
PT2750709T (pt)	2011-09-23	2018-11-22	Xbiotech Inc	Tratamento da caquexia
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1546177A (en) *	1976-11-19	1979-05-16	Biokema Sa	Process for the preparation of a stable injectable solution
JPS5822085B2 (ja) *	1977-07-19	1983-05-06	株式会社ミドリ十字	静注用ガンマ・グロブリン製剤
ES2045027T3 (es) *	1987-08-10	1994-01-16	Miles Inc	Igm purificadas.

1990
- 1990-03-13 CA CA 2049342 patent/CA2049342A1/fr not_active Abandoned
- 1990-03-13 JP JP2505100A patent/JPH04504253A/ja active Pending
- 1990-03-13 WO PCT/US1990/001383 patent/WO1990011091A1/fr not_active Ceased
- 1990-03-13 EP EP19900905158 patent/EP0465513A1/fr not_active Withdrawn

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008303176A (ja) *	2007-06-07	2008-12-18	Kobayashi Pharmaceut Co Ltd	タンパク質含有組成物
US12364754B2 (en)	2011-05-09	2025-07-22	Mayo Foundation For Medical Education And Research	Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab
US10765741B2 (en)	2011-05-09	2020-09-08	Mayo Foundation For Medical Education And Research	Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab
JP2014520535A (ja) *	2011-07-05	2014-08-25	ノボザイムスバイオファーマデーコーアクティーゼルスカブ	アルブミン製剤及び用途
US10844349B2 (en)	2011-07-05	2020-11-24	Albumedix Ltd.	Albumin formulation and use
US10668151B2 (en)	2012-10-01	2020-06-02	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of albumin, paclitaxel, and panitumumab for treatment of cancer
US10413606B2 (en)	2012-10-01	2019-09-17	Mayo Foundation For Medical Education And Research	Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US10279036B2 (en)	2012-10-01	2019-05-07	Mayo Foundation For Medical Education And Research	Antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, and methods of making and using the same
US10307482B2 (en)	2012-10-01	2019-06-04	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of paclitaxel, cetuximab, and albumin
US11648311B2 (en)	2012-10-01	2023-05-16	Mayo Foundation For Medical Education And Research	Cancer treatments
US10376579B2 (en)	2012-10-01	2019-08-13	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of albumin, paclitaxel, and anti-VEGF antibody for treatment of cancer
US10376580B2 (en)	2012-10-01	2019-08-13	Mayo Foundation For Medical Education And Research	Methods of treating cancer with antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel
US10507243B2 (en)	2012-10-01	2019-12-17	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of rituximab, albumin and pacltaxel
US10406224B2 (en)	2012-10-01	2019-09-10	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of paclitaxel, trastuzumab, and albumin
US10279035B2 (en)	2012-10-01	2019-05-07	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of paclitaxel, trastuzumab, and albumin
US10420839B2 (en)	2012-10-01	2019-09-24	Mayo Foundation For Medical Education And Research	Methods for treating CD52-expressing cancers using compositions comprising nanoparticle complexes of paclitaxel, alemtuzumab, and albumin
US10441656B2 (en)	2012-10-01	2019-10-15	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of paclitaxel, cetuximab, and albumin, and methods of making the same
US10471145B2 (en)	2012-10-01	2019-11-12	Mayo Foundation For Medical Education And Research	Methods for treating cancer using nanoparticle complexes of paclitaxel, rituximab, and albumin
US10478495B2 (en)	2012-10-01	2019-11-19	Mayo Foundation For Medical Education And Research	Methods for treating cancer using nanoparticle complexes of paclitaxel, cetuximab, and albumin
US10493150B2 (en)	2012-10-01	2019-12-03	Mayo Foundation For Medical Education And Research	Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin
US12403119B2 (en)	2014-06-13	2025-09-02	Mayo Foundation For Medical Education And Research	Treating lymphomas
US11285221B2 (en)	2014-06-16	2022-03-29	Mayo Foundation For Medical Education And Research	Treating myelomas
US10624846B2 (en)	2014-10-06	2020-04-21	Mayo Foundation For Medical Education And Research	Lyophilized compositions comprising albumin-antibody paclitaxel nanoparticle complexes
US10391055B2 (en)	2014-10-06	2019-08-27	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10610484B2 (en)	2014-10-06	2020-04-07	Mayo Foundation For Medical Education And Research	Methods of using albumin-CD20 paclitaxel nanoparticle complex compositions for treating cancer
JP2019081768A (ja) *	2014-10-06	2019-05-30	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	担体および抗体からなる組成物およびその製造および使用方法
US10966923B2 (en)	2014-10-06	2021-04-06	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10596112B2 (en)	2014-10-06	2020-03-24	Mayo Foundation For Medical Education And Research	Methods of using albumin-antibody nanoparticle complex compositions for treating cancer
JP2017527531A (ja) *	2014-10-06	2017-09-21	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	担体および抗体からなる組成物およびその製造および使用方法
US10772833B2 (en)	2014-10-06	2020-09-15	Mayo Foundation For Medical Education And Research	Albumin-CTLA-4 paclitaxel nanopartilce complex compositions and methods of making and using the same
US10780050B2 (en)	2014-10-06	2020-09-22	Mayo Foundation For Medical Education And Research	Lyophilized compositions comprosing albumin-EGFR paclitaxel nanoparticle complexes
US10300016B2 (en)	2014-10-06	2019-05-28	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10322084B2 (en)	2014-10-06	2019-06-18	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10780049B2 (en)	2014-10-06	2020-09-22	Mayo Foundation For Medical Education And Research	Lyophilized compositions comprising albumin-rankl or albumin-GD2 paclitaxel nanoparticle complexes
JP2021059593A (ja) *	2014-10-06	2021-04-15	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	担体および抗体からなる組成物およびその製造および使用方法
US10993911B2 (en)	2014-10-06	2021-05-04	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10993912B2 (en)	2014-10-06	2021-05-04	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US11433023B2 (en)	2014-10-06	2022-09-06	Mayo Foundation For Medical Education And Research	Albumin-PD-1 paclitaxel nanoparticle complex compositions and methods of making and using the same
JP2022107690A (ja) *	2014-10-06	2022-07-22	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	担体および抗体からなる組成物およびその製造および使用方法
US10596111B2 (en)	2014-10-06	2020-03-24	Mayo Foundation For Medical Education And Research	Methods of making lyophilized compositions comprising albumin-VEGF paclitaxel nanoparticle complexes
US11241387B2 (en)	2015-08-18	2022-02-08	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
JP2018523670A (ja) *	2015-08-18	2018-08-23	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	キャリア結合剤組成物およびそれを作製および使用する方法
JP2021075579A (ja) *	2015-08-18	2021-05-20	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	キャリア結合剤組成物およびそれを作製および使用する方法
US10561726B2 (en)	2015-10-06	2020-02-18	Vavotar Life Sciences LLC	Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment
US11660339B2 (en)	2015-10-06	2023-05-30	Mayo Foundation For Medical Education And Research	Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
US12161718B2 (en)	2016-02-12	2024-12-10	Mayo Foundation For Medical Education And Research	Unit dose of a composition for treating cancer
US11878061B2 (en)	2016-03-21	2024-01-23	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US11305020B2 (en)	2016-03-21	2022-04-19	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
US11655301B2 (en)	2016-04-06	2023-05-23	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
US11160876B2 (en)	2016-09-01	2021-11-02	Mayo Foundation For Medical Education And Research	Methods and compositions for targeting t-cell cancers
US11548946B2 (en)	2016-09-01	2023-01-10	Mayo Foundation For Medical Education And Research	Carrier-PD-L1 binding agent compositions for treating cancers
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US11872205B2 (en)	2016-09-06	2024-01-16	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US11427637B2 (en)	2016-09-06	2022-08-30	Mayo Foundation For Medical Education And Research	Methods of treating PD-L1 expressing cancer
US11311631B2 (en)	2016-09-06	2022-04-26	Mayo Foundation For Medical Education And Research	Paclitaxel-albumin-binding agent compositions and methods for using and making the same

Also Published As

Publication number	Publication date
EP0465513A1 (fr)	1992-01-15
CA2049342A1 (fr)	1990-09-28
WO1990011091A1 (fr)	1990-10-04

Publication	Publication Date	Title
WO1990011091A1 (fr)	1990-10-04	COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM
Garratty	2010	Immune hemolytic anemia associated with drug therapy
US6900184B2 (en)	2005-05-31	Compositions containing pipercillin and tazobactam useful for injection
JP4948407B2 (ja)	2012-06-06	安定化処方
KR20100038100A (ko)	2010-04-12	동결건조된 면역글로불린 제형 및 그의 제조 방법
WO1989011298A1 (fr)	1989-11-30	Formule de reactifs contenant des anticorps
UA82685C2 (uk)	2008-05-12	Стабільна водна композиція наталізумабу та спосіб її отримання
US4439421A (en)	1984-03-27	Stabilized gamma globulin concentrate
JPH11510170A (ja)	1999-09-07	タンパク質の処方
BR112016008576B1 (pt)	2023-03-07	Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
ZA200508315B (en)	2008-04-30	Compositions containing piperacillin and tazobactam useful for injection
CA3162569A1 (fr)	2021-07-29	Formulation d'anticorps stable
WO2004098643A1 (fr)	2004-11-18	Compositions d'injection contenant piperacilline et tazobactame
Pressman et al.	1951	The nature of the combining sites of antibodies: the specific protection of the combining site by hapten during iodination
Garratty et al.	1998	Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta‐lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells
CZ2004189A3 (cs)	2004-05-12	Název neuveden
Okamoto et al.	2023	Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogs
Muschel et al.	1964	Anticomplementary action of endotoxin.
JP2021521232A (ja)	2021-08-26	メグルミン塩を使用して製剤を含むタンパク質を安定化するための方法
Groff et al.	1969	A new and rapid determination of pyridinium aldoximes in blood and urine
Van Furth et al.	1987	Opsonic and physicochemical characteristics of intravenous immunoglobulin preparations
Walter et al.	1972	Membrane surface properties of reticulocytes from rats rendered severely anemic with phenylhydrazine as determined by partition in aqueous phase systems
EP4395816A1 (fr)	2024-07-10	Formulation pharmaceutique d'inhibiteurs de point de contrôle immunitaire
Williams et al.	1989	Vancomycin‐induced red cell aggregation
Garvey et al.	1959	The in vivo stability of antibody